I didn’t expect much. How could there be with data from the s/c study a couple of weeks away? That had to paralyze the FDA and UK. Very good news about the blood brain barrier and 70-75% occupancy of CCR5 in brain. Gives hope to treatment of globalstoma in particular, and all the other cns disorders and tumors. Results likely will be statistically significant based on the testimony of the docs who spoke for the s/c study in 2-3 weeks. No way they won’t be. At least the uplisting possibility should be clearer by the end of next week, too, one way or the other. If sp goes into the $3-3.25 range, I am backing up the truck. I can wait 3 weeks and much longer. No way this drug doesn’t eventually get approval.